ROBINS CHAD M 4

What Happened
Chad M. Robins, CEO and Chairman (Director) of Adaptive Biotechnologies (ADPT), was reported to have acquired a total of 837,033 shares through awards (Form 4 code "A"). The filing shows two acquisitions: 127,813 shares on 2026-03-04 and 709,220 shares on 2026-03-06, each at $0.00 per share (non-cash awards), for a reported cash value of $0.

Key Details

• Transaction dates and prices:
  • 2026-03-04: 127,813 shares @ $0.00 (Award)
  • 2026-03-06: 709,220 shares @ $0.00 (Award)
• Total acquired: 837,033 shares; reported cash value: $0 (these are non-cash awards).
• Shares owned after transaction: Not specified in the provided filing details.
• Notable footnote: The performance share units were granted on March 6, 2023 for a three-year performance period ending March 6, 2026. The issuer certified achievement of the performance goals and the performance share units vested on March 6, 2026 (footnote F1).
• Filing timeliness: Period of report is 2026-03-04 and the Form 4 was filed 2026-03-06; no late filing indication in the provided data.
• Transaction code: "A" = Award/Grant (not an open-market purchase or sale).

Context
These transactions reflect the vesting and settlement of performance-based equity (performance share units), a form of executive compensation contingent on achieving preset goals. Because these are award/vesting events (non-cash), they differ from open-market purchases or sales and do not necessarily indicate immediate personal buying or selling intent. Such awards can dilute existing shares over time and may have tax-withholding mechanics (none reported here).